Oncology

News

Can a new on-body injector version of Sanofi's Sarclisa help it claim market share from J&J's rival top-selling Darzalex in multiple myeloma?

News

AMPLITUDE study of J&J's Akeega could extend the use of PARP inhibitors to hormone-responsive prostate cancer.

News

AstraZeneca and Daiichi Sankyo have revealed the data they hope will move Enhertu into frontline therapy for HER2-positive advanced breast cancer.

News

Bristol Myers Squibb is spending big to avoid being left behind in the race to develop a much-touted class of bispecific antibodies for cancer.

News

AstraZeneca stakes a claim to first-line treatment of HR+ breast cancer with its oral SERD, as Arvinas/Pfizer reveal their second-line data.

News

Gilead lays down a marker for AZ and Daiichi Sankyo to follow as Trodelvy scores in first-line treatment of triple-negative breast cancer (TNBC).